Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
In order to help normalize the topic of bladder leaks, Always Discreet is working with retailers to educate women nationwide. As an example, Procter & Gamble’s Always Discreet brand on Thursday worked with Walmart to launch a new, inspirational video to help women understand how common bladder leaks are and to rethink their negative feelings. “Because many women avoid talking about their bladder leaks, they can often feel alone in their experience, embarrassed to bring up the topic, and hesitant to shop for and wear incontinence products,” stated Barbara Hannah Grufferman, positive living expert, author and Always Discreet spokesperson. “Over the years, I’ve spoken to thousands of women around the country who have bladder leaks, and most women don’t realize how common and normal it is. The good news is that once women realize how many other women experience it too, they feel better about it and themselves,” she said. “That’s what’s been captured in this video, and the hope is that women watch it, make that connection for themselves and feel more confident, empowered and compelled to live their best lives and stand in solidarity with the many other women who experience bladder leaks too.” Read more.
Source: Drug Store News, May 4, 2017
Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study. While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it. The research, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics. “This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.” Read more.
Source: Prostate Cancer News Today, May 4, 2017
Pixie Scientific announced today that it has completed the FDA registration for Pixie Smart Pads and has begun shipping to Early Access customers. The Class I medical device utilizes a patented sensor and software platform to unobtrusively monitor incontinent seniors for an analyte commonly associated with urinary tract infections (UTIs). Pixie Scientific is a healthcare platform technology company focused on improving outcomes by connecting populations at risk with unobtrusive health monitoring—a field Pixie refers to as Connected Care. Pixie’s patented platform consists of a biosensor, a mobile app, and secure cloud architecture which utilizes machine learning for analysis and disseminates information to remote care teams. Clinicians can use this information, along with other symptoms, to order additional patient evaluation or more specific diagnostics in a timely manner—which may lower the rate of co-morbidities and hospital admissions due to UTIs and improve antibiotic stewardship. Read more.
Source: PRNewswire, May 3, 2017
Global medical technology company ConvaTecGroup announced the US launch of the Flexi-Seal PROTECT Fecal Management System on Tuesday, following receipt of 510(k) clearance from the US Food and Drug Administration. The FTSE 100 firm said Flexi-Seal PROTECT FMS was the latest addition to the company’s “market-leading range” of advanced systems developed to manage acute fecal incontinence, and help to reduce the associated risks of skin breakdown and spread of C. difficile infection. Read more.
Source: digitallook.com, May 2, 2017
With nearly 50 percent of women in the United States experiencing symptoms of stress urinary incontinence (SUI), the American Urological Association (AUA), a leading global urology association and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), the premier urological subspecialty society dedicated to improving the art and science of female pelvic medicine and reconstructive surgery, recently released a joint evidence-based clinical guideline on the surgical treatment of SUI in women. SUI is defined as the involuntary leakage of urine due to increased abdominal pressure, which can be caused by such activities as physical exercise, sneezing, laughing or coughing. Approximately half of all women experience SUI symptoms during their lifetime, and many of these women are sufficiently bothered by their symptoms to seek treatment from a physician. Pelvic floor muscle exercises and other nonsurgical treatments can be effective therapies, but many women choose to undergo surgery to treat their SUI symptoms. Read more.
Source: PRNewswire, April 18, 2017
SCA, a company know in the HME industry for its hygiene and incontinence products, such as TENA, will be splitting into two companies, SCA and Essity, with Essity being the company working in the healthcare market. SCA was founded 1929 in Sweden as a forest products company, and over the years the company not only expanded into the international market, but diversified its range of offerings to include incontinence products and other offerings. Most recently, it acquired well-known BSN medical. Eventually, SCA’s health offerings began to eclipse its forest products division. As of 2016, 86 percent of SCA serves the global hygiene and health market, while only 14 percent offers forest products. Moreover, synergies between the two operations have diminished over time, according to SCA. Read more.
Source: HME Business, April 13, 2017
An influential physician task force backed by the U.S. government is softening its opposition to routine prostate cancer screening. In proposed guidelines released today, the U.S. Preventive Services Task Force advised men aged 55 to 69 to discuss the pros and cons of screening with their doctors rather than avoiding it altogether. The task force continued to recommend against a blood test for prostate specific antigen (PSA) in men 70 and older, concluding the potential harms of routine screening still outweigh the benefits for this age group. Since the last guidelines came out in 2012, new evidence has emerged suggesting that PSA tests may help lower the odds that tumors spread to other parts of the body or prove fatal for men aged 55 to 69, said task force chair Dr. Kirsten Bibbins-Domingo, a researcher at the University of California, San Francisco. New evidence also suggests it’s becoming more common for doctors to skip aggressive treatments like surgery or radiation for men with low-risk prostate tumors in favor of doing periodic tests to see if tumors grow, an approach known as active surveillance. Read more.
Source: Reuters, April 11, 2017